Polen Capital's position in Bio-Techne is currently worth $2.45 Million. That's 0.01% of their equity portfolio (80th largest holding). The first Bio-Techne trade was made in Q4 2023. Since then Polen Capital bought shares two more times and sold shares on three occasions. The investor's estimated purchase price is $3.15 Million, resulting in a loss of 22%.
Highlighted on July 10, it was unveiled in an SEC filing that Higgins, Director at Bio-Techne (NASDAQ: TECH ), executed a significant transaction involving t...
Conestoga Capital Advisors, an asset management company, released its “Mid-Cap Strategy” first-quarter 2024 investor letter. A copy of the letter can be down...
Polen Capital, an investment management company, released its “Polen U.S. SMID Company Growth Strategy” fourth-quarter 2023 investor letter. A copy of the sa...
… of Bio-Techne Co. (NASDAQ: TECH – Get Rating) by 305.6% … . Analysts Set New Price Targets TECH has been the subject of … 4.04. Bio-Techne (NASDAQ: TECH – ...